erythromycin has been researched along with iclaprim in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fritsche, TR; Jones, RN; Sader, HS | 1 |
| Barrow, EW; Barrow, WW; Berlin, KD; Bourne, CR; Bourne, PC; Bunce, RA | 1 |
2 other study(ies) available for erythromycin and iclaprim
| Article | Year |
|---|---|
Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.
Topics: Anti-Bacterial Agents; Enterococcus faecalis; Europe; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Hospitalization; Humans; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrimidines; Staphylococcus aureus; Streptococcus; United States | 2009 |
Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum dihydrofolate reductase inhibitor RAB1.
Topics: Anti-Bacterial Agents; Enzyme Inhibitors; Inhibitory Concentration 50; Microbial Sensitivity Tests; Protein Structure, Secondary; Protein Structure, Tertiary; Staphylococcus aureus; Tetrahydrofolate Dehydrogenase | 2010 |